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Abstract
Viruses encode suppressors of cell death to block intrinsic and extrinsic host-initiated death pathways that reduce viral yield
as well as control the termination of infection. Cytomegalovirus (CMV) infection terminates by a caspase-independent cell
fragmentation process after an extended period of continuous virus production. The viral mitochondria-localized inhibitor
of apoptosis (vMIA; a product of the UL37x1 gene) controls this fragmentation process. UL37x1 mutant virus-infected cells
fragment three to four days earlier than cells infected with wt virus. Here, we demonstrate that infected cell death is
dependent on serine proteases. We identify mitochondrial serine protease HtrA2/Omi as the initiator of this caspase-
independent death pathway. Infected fibroblasts develop susceptibility to death as levels of mitochondria-resident HtrA2/
Omi protease increase. Cell death is suppressed by the serine protease inhibitor TLCK as well as by the HtrA2-specific
inhibitor UCF-101. Experimental overexpression of HtrA2/Omi, but not a catalytic site mutant of the enzyme, sensitizes
infected cells to death that can be blocked by vMIA or protease inhibitors. Uninfected cells are completely resistant to
HtrA2/Omi induced death. Thus, in addition to suppression of apoptosis and autophagy, vMIA naturally controls a novel
serine protease-dependent CMV-infected cell-specific programmed cell death (cmvPCD) pathway that terminates the CMV
replication cycle.
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Introduction
Cell death is central to viral infection, as an evolutionarily-
conserved means to eliminate intracellular pathogens and as a way
that lytic viruses mediate release of progeny. Human cytomega-
lovirus (CMV), the major infectious cause of birth defects as well as
an important cause of opportunistic disease worldwide [1],
remains cell-associated during productive replication. Release of
progeny virus depends upon the exocytic pathway [1] and
continues until cells die via a poorly understood fragmentation
process. CMV is well-armed to modulate cell-intrinsic as well as
extrinsic innate and adaptive host clearance pathways [1]. The
product of the UL37x1 gene, vMIA, a potent suppressor of
apoptosis [2–4], also controls the timing of infected cell death [5–
7]. Premature death in vMIA-mutant virus-infected cells reduces
the period of progeny release by three to four days [5–7] without
affecting cell-to-cell spread [5]. All vMIA-mutant viruses exhibit
this premature death phenotype, but the involvement of caspases
and the impact on viral yield varies with CMV strain.
AD169varATCC strain (AD-BAC) depends upon vMIA to a
greater extent [6,7] than TownevarATCC (Towne-BAC), although
vMIA prolongs the period of viral replication and release in both
strains [5]. Importantly, vMIA from either strain retains the
capacity to block caspase-dependent apoptosis [5]. The caspase-
independent death pathway that is blocked by vMIA is not known.
Other cell death suppressors are encoded by CMV [1], but, aside
from vMIA, only UL38 has been implicated in control of infected
fibroblast death to prolong replication [8,9]. Studies to date reveal
a complexity of infected cell death and a need for a more complete
understanding of events that naturally terminate CMV infection.
Major pathways associated with death (apoptosis, necrosis, and
autophagy) are triggered by specific host cell and immune system
initiators and exhibit characteristic molecular events and cell
morphological changes [10–12]. Proteases in the caspase, calpain,
lysosomal cathepsin, and proteasomal serine protease classes are
central to the execution of various death pathways. The fact that
the premature death induced by vMIA-mutant CMV is resistant
to inhibitors of caspases, cathepsins, and calpains [5] suggests a
novel programmed pathway distinct from characterized death
pathways [11,13]. For those viral strains that have been
characterized, infected cell death initiates approximately 7 to 10
days after infection of fibroblasts. In contrast, the premature death
that occurs in vMIA mutant virus infection initiates 3 to 4 days
postinfection [5–7]. The 12–24 h timing of individual cell
fragmentation, association with cytopathic effect (CPE), and
nominal impact of vMIA [5] all suggest that the final stages of
productive replication terminate with a CMV infected cell-specific
programmed cell death (cmvPCD).
Many DNA viruses encode antiapoptotic functions that sustain
replication in the face of cell-intrinsic defenses [14–16]. vMIA
equips CMV to counteract intrinsic host clearance pathways
leading to cell death [5–7]. As an outer mitochondrial membrane
PLoS Pathogens | www.plospathogens.org 1 May 2008 | Volume 4 | Issue 5 | e1000063protein, vMIA sits in a central position analogous to antiapoptotic
Bcl-2 family members Bcl-2 and Bcl-xL [2], and prevents the
formation of a mitochondrial permeability transition pore, release
of cytochrome c and proapoptotic factors into the cytoplasm, and
activation of executioner caspases. Unlike antiapoptotic Bcl-2
family members [2,5,17], vMIA lacks Bcl-2 homology domains but
depends on an antiapoptotic domain that mediates interaction
with GADD45 family members [18,19]. vMIA also recruits BAX
to mitochondria [20,21] and disrupts mitochondrial networks [22].
This disruption normally accompanies BAX oligomerization at the
outer mitochondrial membrane [23,24], although vMIA mutants
that fail to bind BAX continue to disrupt networks [25]. The
vMIA-dependent recruitment of BAX does not lead to the
formation of a transition pore complex or release of proapoptotic
mediators [20,21]. The contribution of BAX oligomerization or
mitochondrial network disruption to cell death suppression
remains to be investigated. Although both of these events are
signs of apoptosis [23,24,26,27] neither mitochondrial network
disruption [28] nor BAX oligomerization [29,30] are sufficient to
induce apoptosis. These alterations are also associated with vMIA-
mediated suppression of cell death during viral infection where the
pathway(s) of death are not fully understood.
Consequences of mitochondrial release of proapoptotic medi-
ators have been extensively studied [10,31–33]. Cytochrome c
controls apoptosome formation and downstream executioner
caspase activation. Endonuclease G and apoptosis-inducing factor
(AIF) promote nuclear events. Mitochondrial release of Smac/
DIABLO and HtrA2/Omi overcomes the activity of inhibitor of
apoptosis proteins (IAPs). The HtrA2/Omi proenzyme is
processed within the mitochondria, removing a mitochondrial
targeting sequence (amino terminal 33 amino acids) and a
transmembrane domain [34–36]. Mature, active HtrA2/Omi
resides in the intermembrane space, and is released into the
cytoplasm through the transition pore complex at the same time as
cytochrome c. Release of the serine protease HtrA2/Omi from
mitochondria can result in two downstream effects: (1) cleavage of
IAPs and an ultimate increase in caspase-dependent death and (2)
trigger IAP-independent, caspase-independent death [37]. This
latter pathway is also induced by extramitochondrial overexpres-
sion of HtrA2/Omi in the cytoplasm [35,37–40]. The role of this
serine protease as an inducer of cell death [38,39] in mammalians
seems opposite the role of the founding member of this protein
family as a pro-survival serine protease in eubacteria [41–43].
Here, we demonstrate the central role of HtrA2/Omi executing a
serine protease-dependent pathway that is controlled by vMIA
during infection.
Results
Premature cell death in the absence of vMIA
We evaluated cmvPCDduring wild type (wt) virus (Towne-BAC,
a GFP-expressing virus [44]) infection by scoring morphological
changes in cells during replication (Fig. 1, supplemental Fig. S1).
Termination of infection was associated with the accumulation of
GFP-positive cell debris that remained associated with the
monolayer (Fig. 1A). Cell fragmentation and death was first
observed at 120 h postinfection in a small percentage of GFP+ foci
(Fig. 1A, Fig. S1). GFP+ dead cell debris was observed only in foci
(Fig. S1). Almost all (.90%) foci showed evidence of fragmentation
by 240 h postinfection (Fig. 1C). Thus, cmvPCD occurred very late
in infection, after maturation and release of progeny virus had
peaked. GFP+ debris was observed much earlier during infection
with vMIA null mutant virus, DUL37x1 (Fig. 1C), although the
fragmentation process appeared similar to wt virus (Fig. 1B, Fig.
S1). As previously reported [5], a majority (70%) of mutant virus
foci contained debris by 120 h due to the single GFP+ cells that
started to fragment between 72 and 96 h postinfection prior to the
formation of foci (Fig. S1). There was a gradual increase in foci
containing fragmented cells between 120 and 192 h postinfection
such that, by 192 h, .90% of foci contained fragmented cells
(Fig. 1C). This was consistent with our previous report showing
both viruses spread with equivalent efficiency but that DUL37x1
induced premature caspase-independent death [5].
DUL37x1-initiated death is a late phase event
Intact GFP+ DUL37x1-infected cells appeared to fragment
before virus spread to form foci (Fig. 1C, Fig. S1) [5]. To
determine whether intact DUL37x1-infected cells released prog-
eny virus before fragmenting, we evaluated the formation of
immediate early nuclear antigen positive (IE+) foci by immuno-
fluorescence. Infected cells became IE+ earlier than they became
GFP+ (Fig. 2). IE+ foci surrounding single GFP+ cells were
detected at 72 h postinfection (Fig. 2A–E), when a majority
(.50%) of GFP+ cells were still intact (Fig. 2A, 2D). Whether
intact or fragmented, .99% of DUL37x1-infected cells produced
foci by 120 h postinfection [5]. Thus, most virus spread occurs
before cells fragmented (Fig. 2A, 2D), suggesting that, like wt,
mutant virus is released before infected cells die (Fig. 1, Fig. S1).
To confirm that the death of mutant virus-infected cells was
dependent on late phase events, the DNA synthesis inhibitor
phosphonoformate (PFA) or the DNA encapsidation inhibitor 2-
bromo-5,6-dichlorobenzimidazole (BDCRB) was added at the
time of CMV infection and cell fate was scored by staining for IE+
cells at 96 h postinfection (Fig. 2B, 2F). PFA inhibits late gene
expression, including GFP, while BDCRB blocks virion matura-
tion but allows late gene expression to proceed [45,46]. Untreated
control or BCDRB-treated infected cultures appeared similar,
whereas PFA-treated cultures contained single IE+ cells that
remained GFP-. Only about 30% of GFP+ cells or debris in
untreated DUL37x1-infected cells were IE+ at 96 h postinfection
Author Summary
Cellular suicide is an effective host defense mechanism to
control viral infection. Host cells encode proteins that
induce infected cell death while viruses encode proteins
that prevent death and facilitate viral replication. Human
cytomegalovirus encodes vMIA to suppress host-initiated
death pathways. Cytomegalovirus infection is controlled
by the evolutionarily ancient mitochondrial serine prote-
ase, HtrA2/Omi. HtrA2/Omi levels rise dramatically within
mitochondria at late times during viral infection, eventually
overcoming viral control of a cell death pathway that is
dependent on this serine protease and independent of the
well-studied apoptotic cell death pathway that conven-
tionally depends upon a class of proteases called caspases.
vMIA naturally counteracts HtrA2/Omi-dependent cell
death and allows infected cells to survive and produce
virus for several days. The natural inhibitory role of vMIA
can be overwhelmed by overexpression of HtrA2/Omi in
virus-infected cells, but uninfected cells are insensitive to
HtrA2/Omi-induced death. The broad distribution of
HtrA2/Omi within mammalian host species suggests this
may represent an ancient antiviral response or a process of
viral detente that establishes the timing of infection. Either
way, the success of cytomegalovirus rests in the balance
between cell death initiation and the viral cell death
suppressor vMIA.
HtrA2/Omi and vMIA Control of cmvPCD
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IE expression was lost as cells fragmented. BDCRB-treated cells
exhibited a pattern similar to untreated cells, suggesting that
fragmentation was triggered by events prior to DNA encapsida-
tion. All infected cells in PFA-treated cultures remained IE+
(Fig. 2F) and did not fragment, suggesting that initiation of cell
death was dependent on events that followed viral DNA synthesis.
Thus, initiation of death was dependent on cellular changes
associated with viral DNA replication and/or late phase gene
expression.
Figure 1. Pattern and timing of cmvPCD in Towne-BAC and DUL37x1-infected cells. Images of infected cell foci (multiplicity of infection
[MOI] of 0.01) showing cmvPCD in Towne-BAC (A) and DUL37x1 (B) infected cells at 120 h postinfection (hpi). GFP expression by the viruses was used
to identify foci of infected cells. Original magnification 6400. (C). The mean percentages (6standard deviation) of GFP+ foci with fragmented cells
based on counting 400 infected foci each day. Infection was with a MOI of 0.0001. The mean6sd is depicted in all figures, except where indicated.
doi:10.1371/journal.ppat.1000063.g001
Figure 2. cmvPCD follows maturation and release in Towne-BAC and DUL37x1-infected cells. Representative fluorescent images of
immediate early positive (IE+) nuclei in foci surrounding an intact, live (A) or fragmented, dead GFP+ cell (B). (GFP=green, indirect fluorescence of IE
antigen=red; original magnification 6200). (C–E) Percentage of total GFP+ (C), live GFP+ (D), or dead (debris) (E) GFP+ cells forming IE1+ foci at 72
and 96 h postinfection with DUL37x1 or Towne-BAC (MOI of 0.001). A total of 300 GFP+ cells per virus were evaluated at each time for the experiment
depicted. (F) Percentage of IE+ cells (live) at 96 h postinfection with DUL37x1 (MOI of 0.003), comparing untreated cultures to cultures treated with
300 mg/ml PFA or 20 mM BDCRB from 1 h postinfection. Data are from a representative experiment in which a total of .1000 infected cells/foci were
evaluated for each condition.
doi:10.1371/journal.ppat.1000063.g002
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death
We evaluated cell morphology [11] associated with death in
DUL37x1 and wt virus-infected cells (Fig. 3). Late in CMV
infection, inclusions form within enlarged cells coincident with
replication and maturation processes that take place in the nucleus
as well as in the cytoplasm. At 72 h postinfection, DUL37x1 and
wt virus-infected cells exhibited similar nuclear and cytoplasmic
inclusions [1,47,48] as well as enlarged cell CPE (Fig. 3A, 3F and
Fig. S2) [5]. Stain for total nuclear DNA revealed a diffuse pattern
(Fig. 3F, Fig. S2) that became distorted (Fig. 3G) and progressed
through shrinkage and collapse and loss of nuclei (Fig. 3H–J) as
cells fragmented (Fig. 3C–E). A similar process accompanied
fragmentation in mutant or wt infected cells. The fragmentation
process produced cell debris (Fig. 3E) lacking signs of DNA
(Fig. 3J). Loss of nuclei scored by DNA stain or IE antigen (Fig. 2)
was similar. Cell debris remained GFP+ and unstained by
ethidium homodimer (Fig. S3), suggesting a non-necrotic death.
Fragmentation was not synchronous in infected cultures, such that
only 10% of infected cells exhibited intermediate fragmentation
patterns (e.g. Fig. 3B–D) at any time (Fig. 3K and Fig. S1). The
same types of morphological changes that started at 72 h in
DUL37x1-infected cultures started at 120 h postinfection in
Towne-BAC-infected cells (Fig. S1 and S4). The fragmentation
of GFP+ cells (Fig. 1), loss of IE+ cells (Fig. 2) and loss of DNA+
nuclei (Fig. 3) were all characteristic of cmvPCD in wt and
premature death in mutant virus-infected cells.
Serine proteases induce cmvPCD
Previous work showing that caspases, cathepsins, or calpains
were not involved in DUL37x1-initiated premature death [5], lead
us to evaluate the contribution of cellular serine proteases to this
process. We started by assessing the impact of a broad-spectrum
inhibitor, TLCK [49–62], because this inhibitor does not affect the
Figure 3. cmvPCD proceeds through cell fragmentation and nuclear collapse in the absence of chromatin condensation.
Representative images showing stages of infected cell fragmentation and death in DUL37x1 infected cultures (collected at 72 h postinfection).
Fluorescent micrographs of GFP+ virus-infected cells (A–E) and Hoechst-stained nuclei (F–J) associated with fragmentation. (A, F) Cytomegalic
infected cell without signs of fragmentation, (B, G) initial stages of fragmentation with intact nucleus, (C, H) fragmented cell body with collapsed
nuclear body, (D, I) fragmented cell body with residual nuclear body, and (E, J) fragmented cell debris without residual nuclear material. Original
magnification 61000. (K) Counts of GFP+ intact infected cells (Intact Cell), Hoechst positive fragmented cell bodies (Fragmented Cell), and Hoechst
negative fragmented cell debris (Debris) at 72 and 96 h postinfection with DUL37x1 (MOI of 0.002). Data are from a representative experiment in
which a total of 750 infected cells/foci were evaluated for each time.
doi:10.1371/journal.ppat.1000063.g003
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sufficient to block cellular serine proteases [63]. Addition of TLCK
(11, 33, or 100 mM) to infected cultures at 30 h lead to a
concentration-dependent reduction in cell fragmentation at 72 h
postinfection (Fig. 4A). These concentrations of inhibitor did not
reduce virus yields (Fig. 4B). Thus, TLCK inhibited premature cell
death without any impact on virus replication. When TLCK was
added at 30 h and fragmented cells were counted at 72, 96, and
120 h postinfection (Fig. 4C), cell death was reduced approxi-
mately twofold, suggesting that serine proteases play a central role
in the timing of fragmentation. Despite experiment-to-experiment
variability in the levels and rate of fragmentation death observed
between 72 and 120 h postinfection, TLCK consistently inhibited
this process (Fig. 4A and C) and increased the proportion of live,
intact cells while absolute numbers of GFP+ cells or debris
remained the same (Fig. 4D). This result implicated serine
proteases early in the premature death induced by mutant virus.
Previously, we reported that the pan-caspase inhibitor
zVAD.fmk had no effect on DUL37x1-induced premature death
[5]. To determine whether caspases influenced death levels when
serine proteases were inhibited, we applied zVAD.fmk alone as
well as in combination with TLCK. The caspase inhibitor did not
influence the serine protease-dependent process (Fig. 4E). In
contrast, zVAD.fmk showed the expected [5,6,64] inhibition of
apoptosis induced in CMV strain AD169varATCC infected cells
(Fig. 4F). Thus, these data imply that cmvPCD is controlled by
serine proteases that work independent of caspases.
The serine protease HtrA2/Omi initiates cmvPCD
To determine the timing of serine protease activity in
controlling premature death, TLCK was added to DUL37x1-
infected cells at 30, 54, or 78 h. Addition of TLCK at each of these
times was found to dramatically reduce the level of death at 96 h
postinfection (Fig. 5A). These results suggest serine proteases act
Figure 4. The serine protease inhibitor TLCK prevents DUL37x1-induced premature cmvPCD. (A) Percentage of dead GFP+ infected cells
at 72 h postinfection in untreated cultures (U) or cultures treated with 11, 33, or 100 mM TLCK from 30 h postinfection with DUL37x1 (MOI of 0.001). A
total of 300 cells/foci were evaluated at each condition. (B) Virus yield at 120 h postinfection from cell cultures left untreated (U) or treated with 11,
33, or 100 mM TLCK from 30 h postinfection with DUL37x1 or Towne-BAC (MOI of 0.001). (C) Percentage of fragmented GFP+ cells at 72, 96, or 120 h
postinfection with DUL37x1 (MOI of 0.005) in control cultures or cultures treated with 33 mM TLCK from 30 h postinfection. A total of 1450 cells/foci
were evaluated at each condition. (D) Absolute numbers of live or dead GFP+ cells at 96 h postinfection with DUL37x1 (MOI of 0.001) in untreated
cultures or cultures treated with 33 mM TLCK from 30 h postinfection. (E) Percentage of dead GFP+ cells at 96 h postinfection with DUL37x1 (MOI of
0.005) in untreated cultures or cultures treated with 33 mM TLCK, 25 mM zVAD.fmk, or 0.05% DMSO, added from 30 h postinfection. A total of 300
cells/foci were evaluated at each condition. (F) Percentage of live cells at 48 h postinfection with AD169varATCC (MOI of 3) following treatment with
anti-Fas antibody to induce apoptosis in control cultures or cultures treated with 6, 12, or 25 mM zVAD.fmk, added at 24 h postinfection.
doi:10.1371/journal.ppat.1000063.g004
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importance of these proteases late in infection. Taken together with
data on timing of the death stimulus (Figs. 2 and 3, and [5]), serine
proteases active late in CMV infection may either trigger or play an
intermediaryroleinthe celldeathpathway. To determine thetiming
of serine protease activity in wt virus-induced cmvPCD, TLCK was
added at 30, 54, and 78 h (Fig. 5B). Addition of TLCK at each of
these times effectively reduced cell fragmentation at 144 h
postinfection, suggesting that proteases active after the 78 h time
period played a criticalroleduringwtvirusinfection as well(Fig.5B).
These data demonstrate a common serine protease cell death
pathway terminates mutant or wt virus infection, and demonstrate
that the premature death in mutant virus infected cells follows a
similar pathway as cmvPCD. Differences in timing show the
importance of vMIA control in the timing of cmvPCD.
One mitochondrial serine protease, HtrA2/Omi, has been
implicated in cell death pathways and exhibits sensitivity to TLCK
[40,65–67]. The specific HtrA2/Omi inhibitor UCF-101 [68] was
added to DUL37x1- or Towne-BAC-infected cultures (Fig. 5C–E)
at a concentration (10 mM) anticipated to minimize a previously
recognized impact on other cellular targets [69]. UCF-101
reduced death when added to DUL37x1 or Towne-BAC-infected
cultures at 30 or 54 h, implicating HtrA2/Omi as a mediator of
cmvPCD (Fig. 5C–D). Although UCF-101 added at 54 h reduced
death of DUL37x1-infected cells at 96 h postinfection, addition at
78 h was ineffective (Fig. 5C). Towne-BAC-associated death at
144 h was reduced by UCF-101 added as late as 102 h, but not
when added at 126 h (Fig. 5D). UCF-101 treatment did not
reduce viral yields (Fig. 5E). Most importantly, these data suggest
that events over the 24 to 48 h preceding fragmentation of cells are
influenced by HtrA2/Omi, regardless of whether considering the
premature cmvPCD in mutant virus infected cells or cmvPCD in
wt infection. The differences between UCF-101 and TLCK
addition at 78 h (Fig. 5A) may be due to the effectiveness of these
Figure 5. Inhibitors of serine protease HtrA2/Omi suppress cmvPCD. (A) Percentage of dead GFP+ cells at 96 h postinfection with DUL37x1
(MOI of 0.01) in cultures treated with 100 mM TLCK from 30, 54, or 78 h postinfection relative to untreated cultures (U). 3000 cells/foci were evaluated
at each condition. (B) Percentage dead GFP+ cells at 144 h postinfection with Towne-BAC (MOI of 0.03). 9000 cells/foci were evaluated at each
condition. (C) Percentage of dead GFP+ cells at 96 h postinfection with DUL37x1 in cultures treated with 10 mM UCF-101 from 30, 54, or 78 h
postinfection relative to untreated cultures (U). 3000 cells/foci were evaluated at each condition. (D) Percentage of dead GFP+ cells at 144 h
postinfection with Towne-BAC (MOI of 0.03). A total of 9000 cells/foci were evaluated at each condition. Data in A–D is depicted relative to untreated
controls, which were assigned a value of 100%. (E) Yields of virus at 168 h postinfection (MOI of 0.01) with DUL37x1 or Towne-BAC in untreated
cultures or cultures treated with UCF-101 from 30 or 54 h postinfection.
doi:10.1371/journal.ppat.1000063.g005
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contribute to cmvPCD. Overall, these data demonstrate that
UCF-101 specifically reduces infected cell death and implicate the
serine protease HtrA2/Omi in the pathway. Further, these data
implicate HtrA2/Omi as a target of vMIA modulation.
HtrA2/Omi levels increase late in infection
To determine the impact of mutant or wt virus infection on
HtrA2/Omi expression levels and subcellular localization as well
as to investigate any impact of vMIA on HtrA2 expression,
immunoblot analysis was carried out on Towne-BAC infected cells
(Fig. 6). Levels of mature 36 kDa HtrA2/Omi levels were similar
to uninfected cells at 24 h, but increased by 48 h and continued to
accumulate over the course of infection (Fig. 6A–B). Comparisons
of mutant and wt infected cells showed similar accumulation of
HtrA2 by 48 h (Fig. 6B, Fig. S5). Premature cmvPCD initiated in
mutant virus-infected cells prevented comparisons by immunoblot
later in infection; however, immunofluorescence analyses at 96 h
postinfection confirmed the dramatically increased HtrA2/Omi
levels in mutant or wt virus-infected cells (Fig. 6C–H and Fig. S6).
HtrA2/Omi colocalized with the mitochondrial membrane
potential marker MitoTracker Red (Fig. 6C, 6F and Fig. S6) at
late times of infection with either virus. These data indicate that
HtrA2/Omi levels increase within mitochondria before the
initiation of cmvPCD. vMIA does not alter expression pattern or
mitochondrial localization of this protease but nevertheless
prevents death.
Mitochondria in wt CMV infected cells followed the expected
[22] reticular to punctate transition associated with disruption of
mitochondrial networks (Fig. 6F, 6L, and Fig. S6) and mutant
virus-infected cells retained a reticular pattern (Fig. 6C, 6I and Fig.
S6) when stained for HtrA2/Omi, cytochrome c, mitochondrial
Figure 6. HtrA2/Omi expression increases following CMV infection. (A–B) Immunoblot analyses of HtrA2/Omi in lysates of mock-infected HF
(M) or HF infected (MOI of 3) with Towne-BAC or DUL37x1 for 24, 48, 72, 96, or 120 h and control cell lysates from HeLa cells transfected with HtrA2/
Omi expression plasmid (+) or control plasmid (2). The expected migration of the 49 kDa immature, pro-HtrA2/Omi and 36 kDA mature, HtrA2/Omi
was calculated based on migration of molecular weight markers (not shown). Immunoblot detection of HtrA2, b-actin and IE1 are shown. (C–N)
Immunofluorescent images of HtrA2/Omi (C, F) and cytochrome c (I, L) (red), and GFP fluorescence (green) (D, G, J, M) and merged images (E, H, K, N)
at 72 h (C–H) or 96 h (I–N) postinfection (MOI of 0.001) with DUL37x1 (C–E, I–K) or Towne-BAC (F–H, L–N). Original magnification 61000.
doi:10.1371/journal.ppat.1000063.g006
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indicated that mitochondria retained a similar membrane
potential despite this difference in morphology due to vMIA
(Fig. S6). When the kinetics of the reticular to punctate transition
was evaluated in Towne-BAC-infected cells, almost all ($90%) of
cells contained reticular mitochondria at 48 h, but transitioned to
punctate by 96 h. In contrast, DUL37x1-infected cells retained a
reticular morphology ($80%) throughout infection. These data
suggest that a vMIA-dependent process disrupts reticular mito-
chondria beginning at 48 h postinfection and this change in
mitochondrial organization may contribute to cell survival.
Despite this striking difference in mitochondria, the organelles of
the secretory apparatus that form the viral assembly compartment
at late times of infection [48,70] were similar in either virus
infection (Fig. S2, Fig. S6). Thus, disruption of mitochondrial
networks by wt virus may contribute to control of HtrA2/Omi-
dependent death and the failure of mutant virus to induce these
changes may lead to premature HtrA2/Omi-dependent death.
We sought to determine whether mitochondria released
cytochrome c prior to premature cmvPCD. Cells that had not
yet started to fragment all showed reticular cytochrome c staining
(Fig. 6 and Fig. S6) whereas diffuse staining was detected only as
cells became highly fragmented (Fig. S7). These data suggest that
release of cytochrome c follows the fragmentation that character-
izes cmvPCD.
HtrA2/Omi overexpression early after infection blocks
CMV replication
To directly address the impact of HtrA2/Omi overexpression
on the cell fate, full-length HtrA2/Omi as well as a catalytic site
mutant (HtrA2S306A) [34] were transiently expressed in unin-
fected and virus-infected cells. Initially, expression levels and
impact on uninfected cell viability were assessed (Fig. 7A–H, Fig.
S8). HtrA2/Omi (or mutant HtrA2/Omi) overexpression did not
induce death in uninfected HFs (Fig. 7H) or HeLa cells (Fig. S8),
consistent with published characterization of full-length protease
[37]. Immunofluorescence patterns revealed the expected mito-
chondrial localization at 48 h post transfection (Fig. 7A–F), and
immunoblot analyses using HeLa cells indicated equivalent
expression levels of the wt and mutant protease (Fig. 7G). To
determine the impact of HtrA2/Omi overexpression on infected
cells, Towne-BAC or DUL37x1 were cotransfected with HtrA2/
Omi or HtrA2S306A expression plasmids (Fig. 7I) and assessed for
spread to form foci [71]. By 10 days posttransfection, wt and
mutant BACmids had produced comparable numbers of plaques,
as expected [5]. Cotransfection of HtrA2/Omi expression plasmid
reduced the plaquing efficiency .10-fold compared to vector
control or HtrA2S306A mutant (Fig. 7I). These data show that
overexpression of catalytically active HtrA2/Omi prevents plaque
formation independent of vMIA expression.
To determine whether the reduction in plaguing efficiency
following overexpression of HtrA2/Omi was due to cell death
induction, the fate of individual cells was monitored (Fig. S9).
When Towne-BAC was cotransfected with HtrA2/Omi or
HtrA2S306A, individual GFP+ cells were observed at 48 h,
although even at this time the levels could be lower in cells
receiving the protease active form (Fig. 7J–K). HtrA2/Omi/GFP+
cells began to fragment by 72 h posttransfection (Fig. 7J) and were
lost from cultures by 168 h (Fig. S9). HtrA2/Omi overexpression-
induced death required the active protease, based on the failure of
HtrA2S306A to induce death (Fig. 7J) as well as on the ability of
the inhibitor UCF-101 to block HtrA2/Omi overexpression-
induced death (Fig. 7K). The numbers of GFP+ cells (Fig. 7J) or
plaques (Fig. 7I) that formed following cotransfection of Towne-
BAC with HtrA2S306A could not be distinguished from
transfection of Towne-BAC with vector. These data show that
overexpression of catalytically active HtrA2/Omi induces infected
cell death that is independent of vMIA expression. The sensitivity
of virus-infected cells and lack of impact on uninfected HFs
(Fig. 7H) supports the specific role of HtrA2/Omi in a novel cell
death pathway in CMV-infected cells.
A role of vMIA in HtrA2-induced death was investigated using
the cotransfection assay carried out using lower doses of expression
plasmids as well as using vMIA-expressing cells. Cotransfection of
HtrA2/Omi expression plasmid at a 25 or 30-fold lower level
revealed a differential impact on these viruses (Fig. 8A), where
Towne-BAC exhibited a greater resistance to HtrA2/Omi-
induced death. These conditions were also employed to demon-
strate that vMIA overexpression overcame HtrA2/Omi-induced
death (Fig. 8A). To address the role of vMIA further, HFs as well
as HFs stably transduced with retroviruses expressing Myc-tagged
vMIA or mutant protein [18] vMIAmut (Fig. 8B–C) were infected.
As expected [5], vMIA-HFs suppressed the premature cmvPCD
when assessed at 96 and 120 h postinfection, whereas vMIAmut-
HF or nontransduced control HFs did not (Fig. 8B). These data
suggest the intact antiapoptotic domain of vMIA is required to
control premature cmvPCD. The experimental plating efficiency
of DUL37x1 virus was the same on either cell line (Fig. S10 and
[5]). These results were consistent with a role for vMIA in
controlling kinetics of cmvPCD and suggest that similar functional
domains of vMIA are required in suppression of apoptosis or
HtrA2-dependent cmvPCD. Immunoblot analyses were used to
compare transduced vMIA (or vMIAmut) levels relative to native
viral expression (Fig. 8C). The lower levels of transduced gene
expression likely contribute to the death suppression observed
(Fig. 8B). Rescue viruses derived from DUL37x1 confirmed that
an intact UL37x1 locus is sufficient to completely control
premature death, mitochondrial organization, and viral yield
(Fig. 8D, Fig. S10). Overall, these data confirm the critical role of
vMIA as a determinant of cmvPCD when induced by overex-
pression of HtrA2/Omi transfection or during the late phase of
infection. Thus, DUL37x1 infection sensitizes to the prodeath
impact of HtrA2/Omi, and vMIA controls HtrA2/Omi prodeath
pathways during wt CMV infection.
vMIA antiapoptotic function remains intact and
independent of HtrA2/Omi during infection
In order to determine whether the antiapoptotic activity of
vMIA is preserved in cells where HtrA2/Omi is overexpressed, we
performed experiments with HtrA2/Omi expression constructs in
HeLa cells exposed to Fas-mediated apoptosis (Fig. 9) [2,19].
Immunofluorescence analyses showed expected levels and local-
ization of HtrA2/Omi and vMIA in transfected cells (Fig. 9A–I).
These analyses indicated that vMIA and HtrA2/Omi (or
HtrA2S306A) colocalize with mitochondria under all conditions.
Introduction of HtrA2/Omi or mutant expression constructs did
not influence the antiapoptotic activity of vMIA (Fig. 9J–L),
consistent with previous work showing vMIA-dependent anti-
apoptotic function is active at late times of infection [5,6].
Together, these data suggest that HtrA2/Omi does not interfere
with vMIA-mediated control of apoptosis.
Increased serine protease accumulation in cells
undergoing premature cmvPCD
To directly visualize levels of serine proteases in infected cells,
the fluorescent reagent sulforhodamine 101-leucine chloromethyl
ketone (SLCK) was used to reveal the distribution and activity of
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cultures (Fig. 10). By day 5, foci with brightly stained GFP+ debris
was observed in cultures infected with either virus (Fig. 10E–F),
although fragmentation was rare in wt virus-infected cultures at
this time. The SLCK staining pattern was distinct in DUL37x1-
infected cells and included bright SLCK+ debris (Fig. 10A) that
was distinguishable from Towne-BAC infected cells by differences
in the amount of staining as well as the size and distribution of
Figure 7. Transient overexpression of HtrA2/Omi induces early death in CMV-infected but not uninfected cells. (A–F)
Immunofluorescent images of HtrA2/Omi (A–C) and GFP fluorescence (D–F) following cotransfection of HF with GFP expression plasmid together
with empty vector, HtrA2/Omi, or HtrA2S306A expression plasmids. Original magnification 6400. (G) Immunoblot depicting 49 kDa, immature and
36 kDA, mature forms of HtrA2/Omi and HtrA2S306A as well as b-actin control in transfected HeLa cell lysates. (H) Percentage of live HFs at 120 h
post cotransfection of GFP expression plasmid with vector, HtrA2/Omi, or HtrA2S306A expression plasmids. (I) Number of viral plaques 10 days
following cotransfection of DUL37x1 or Towne-BAC DNA (500 ng) with 800 ng vector, HtrA2/Omi, or HtrA2S306A expression plasmids. (J) Number of
live (intact) cells in cultures at 48 or 72 h following transfection with Towne-BAC DNA (300 ng) alone or with 333 ng of HtrA2 or HtrA2S306A
expression plasmids. (K) Number of live (intact) cells (6range) at 48 or 72 h post transfection with Towne-BAC DNA (500 ng) and 300 ng of vector or
HtrA2/Omi expression plasmid with or without addition of 10 mM UCF-101 from 6 h.
doi:10.1371/journal.ppat.1000063.g007
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infected cells in each plaque were brightly fluorescent (Fig. 10C)
whereas cells infected with wt virus (Fig. 10D) showed only
SLCK+ debris. SLCK staining patterns did not appear to be
mitochondrial at any time in either virus infection. These patterns
were distinct from HtrA2/Omi (Fig. 6C), suggesting that SLCK
labeling detected serine proteases in addition to HtrA2/Omi.
Addition of 0.1 or 1 mM TLCK reduced but did not eliminate
SLCK binding to mutant virus-infected cells, consistent with the
induction of serine proteases (Fig. S11). Overall, .50% of GFP+
cells in DUL37x1 plaques also labeled with SLCK. SLCK staining
was reduced to #30% by addition of 100 mM TLCK. Thus,
SLCK revealed a higher level of protease activation in CMV
infected cells that were susceptible to premature cmvPCD. This
data suggests that vMIA may control a broader serine protease-
dependent death pathway by counteracting mitochondrial HtrA2/
Omi during viral infection.
Discussion
CMV replicates in the nucleus, matures in the cytoplasm and is
released into the surrounding medium or adjacent cells over the
course of a 7 to 10 day replication cycle [1]. Host cells are
dramatically reprogrammed for production of progeny virus until
death occurs via a process that begins late in CMV infection,
associated with late gene expression that drives CPE and cell cycle
dysregulation [73–76]. In an effort to define viral and cellular
contributions to morphological and biochemical events that
terminate CMV infection, we have discovered the key role of
mitochondrial HtrA2/Omi and a novel cell death pathway. This
cellular serine protease appears to be responsible for induction of
cmvPCD following a pathway that is held in balance by the viral
cell death suppressor, vMIA. vMIA resides in the mitochondrion
where it is a potent suppressor of cytochrome c release, thereby
preventing activation of executioner caspases during apoptosis [2–
Figure 8. vMIA suppression of HtrA2/Omi-dependent cmvPCD. (A) Average number of live cells (6range) in cultures at 72 h post transfection
of Towne-BAC DNA (500 ng) with 12 ng of HtrA2/Omi expression plasmid or control vector or post transfection of DUL37x1 DNA (500 ng) with 12 ng
of HtrA2/Omi expression plasmid in the absence or presence of 15 ng vMIA-encoding plasmid or 12 ng of control vector in the absence or presence
of 15 ng vMIA-encoding plasmid. (B) Percentage of dead cells at 96 and 120 h postinfection (MOI of 0.0001) with DUL37x1 in HF, vMIAmut-HF, or
vMIA-HF cultures. 400 cells/foci were evaluated for each condition. (C) Immunoblot detection of native vMIA (vMIA-nat.), vMIA-myc, and vMIAmut-
myc in cell lysates collected at various h postinfection (MOI of 3) with DUL37x1 or Towne-BAC. Top, a-myc antibody; bottom, a-vMIA antibody. (D)
Percentage of dead cells at 72, 96, 120, and 148 h postinfection (MOI of 0.0001) with DUL37x1, Towne-BAC, DUL37x1R1, or DUL37x1R2. 100 cells/foci
were evaluated for each condition.
doi:10.1371/journal.ppat.1000063.g008
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distinct and nonoverlapping role suppressing death induced by
HtrA2/Omi during the late phase of viral infection. This cmvPCD
pathway is triggered only in the context of infection. Late phase
infected cell events promote cell fragmentation together with
collapse, shrinkage, and loss of nuclei in a pathway that is
dependent on HtrA2/Omi protease activity and associated with
the activation of cytoplasmic serine proteases that may act as
executioners. HtrA2/Omi levels rise before induction of death,
consistent with a central role of this protease in initiation of
cmvPCD. Suppression of this death pathway, like suppression of
apoptosis, is associated with global disruption of mitochondrial
networks by vMIA. Unlike apoptosis, however, cmvPCD appar-
ently does not require cytochrome c release from mitochondria to
trigger downstream events. Further, HtrA2/Omi remains mito-
chondrial late during infection suggesting death may be initiated
by the activity of the intramitochondrial protease, which raises an
interesting question as to how transduction of the death signal
occurs. Our data reveal a pathway that is triggered by high
intramitochondrial HtrA2/Omi protease and controlled by vMIA.
Although vMIA-mutant virus undergoes premature cmvPCD,
the fragmentation process is similar to cmvPCD in wt virus-
infected cells. The difference appears to be in timing of cell death.
vMIA delays death for several days beyond the initiating trigger
which is coincident with the late phase of replication. Although
induction of HtrA2/Omi is independent of vMIA, the impact of
induction appears to be the target of vMIA function at the
mitochondria where both reside. Suppression of cmvPCD benefits
the virus by extending the period of virus production by infected
cells [5], although cultured fibroblasts show only slight reduction
in yield and cell-to-cell transmission in the absence of vMIA. A
prolonged period of virus production increases the amount of virus
Figure 9. HtrA2/Omi overexpression does not impede vMIA antiapoptotic activity. (A–I) Immunofluorescent images of vMIA (A–C) or
HtrA2/Omi (D–F) as well as Hoechst staining (G–I) in HeLa cells following transfection with vMIA together with vector, HtrA2/Omi, or HtrA2S306A
expression plasmids. Original magnification 6400. (J–L) GFP+ cell number as a percentage of control wells (vector) of HeLa cells cotransfected with
vMIA (1 mg) or GFP expression plasmids and 1 mg (J), 2 mg (K), or 3 mg (L) quantities of vector, HtrA2/Omi, or HtrA2S306A DNA. GFP+ cell numbers in
vMIA plus vector wells were assigned values of 100%.
doi:10.1371/journal.ppat.1000063.g009
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settings. A delay in fragmentation would also delay phagocytosis and
clearance of virus-infected cells [77]. HtrA2/Omi-dependent death
may be viewed as an intrinsic host antiviral process analogous to
apoptosis. vMIA control of HtrA2/Omi-mediated death is analo-
gous to control of apoptosis, as both appear to be independent cell-
intrinsic mechanisms of pathogen control. Importantly, vMIA
appears to provide concurrent protection from both pathways.
vMIA disruption of reticular networks and organization of
mitochondria [22] is independent of HtrA2/Omi accumulation
within mitochondria, but does correlate with cell death suppres-
sion activity. Thus, DUL37x1-mutant virus-infection preserves
mitochondrial networks throughout infection, during HtrA2/Omi
accumulation and initiation of premature cmvPCD. In contrast,
wt virus infected cells support the same accumulation of HtrA2/
Omi and a vMIA-driven disruption of mitochondrial networks but
survive. The correlation between this vMIA-dependent disruption
and cell death protection suggests that punctate mitochondria may
be more resistant to the stress induced by late phase events.
Reticular mitochondria are known to rapidly disseminate Ca
++ or
ATP signals; whereas, punctate mitochondria have slower
responses to changes in intracellular mediators [78]. Additional
experiments will be needed to understand the mechanism
underlying resistance of punctate mitochondria to death, whether
mediated via caspases or HtrA2/Omi.
Emerging evidence suggests vMIA, viral strain differences, and
cellular factors contribute to the control of mitochondria and
death. Thus, AD-BAC kills cells earlier [6] and disrupts
mitochondrial networks by 24 h postinfection [22] whereas
Towne-BAC disruption occurs later, by 48 h postinfection and
cells die later. vMIA associates with the outer mitochondrial
membrane within 24 h [79,80]. AD-BAC (or its parent AD169-
varATCC) depends upon vMIA to suppress caspase-dependent
apoptosis that develops by 48 to 72 h postinfection. Towne-BAC
(or its parent TownevarATCC) depends on vMIA to suppress
caspase-independent, HtrA2-dependent cell death that develops
by 72 to 96 h postinfection. It remains to be seen whether vMIA
suppresses both pathways in cells infected with strains like AD-
BAC. Accumulation of HtrA2/Omi occurs in other viral strains
(McCormick, unpublished), underscoring the overall importance
of the process described here. There are many potential factors
contributing to qualitative or quantitative differences in the way
characterized viral strains initiate and control death, with
apoptosis apparently predominating in some settings and HtrA2-
mediated death predominating in others. We focused here on
dissecting the novel death pathway in Towne-BAC-infected cells,
to characterize a novel HtrA2/Omi pathway that is independent
of apoptosis.
cmvPCD may be influenced by or even associated with a
number of additional modulatory effects of this virus that impact
late times of infection, including dysregulation of the cell cycle
[73–76], disruption of p53 activation [81], DNA damage response
[82,83] and unfolded protein response [84] that all remain
incompletely understood. vMIA may reduce ATP levels during
infection as it does in established cell lines. Although suggested to
control late CPE in AD-BAC derivatives [85] vMIA has no impact
on development of CPE in Towne-BAC derivatives. Any vMIA-
specific reduction in ATP levels is likely highly coordinated with
other viral processes contributing to late CPE. CMVs encode
multiple factors that target mitochondria [86,87], regulate
expression of mitochondrial proteins [75] and even stimulate
mitochondrial DNA synthesis [88] suggesting viral control of
mitochondria functions is complex. The vMIA-specific impact on
ATP levels as related to HtrA2/Omi remains unknown but may
certainly be a feature of control. As an event that occurs very late
in replication, cmvPCD is crucial to sustaining viral infection in
individual cells. Our observations that either mutation of vMIA or
premature overexpression of HtrA2/Omi levels dramatically alters
the timing of death indicate that these two may balance each
another in controlling cmvPCD.
Figure 10. SLCK localization within infected cells. Images of fluorescent serine protease substrate SLCK localization (A–D) and GFP fluorescence
(E–H) in DUL37x1 (A, C, E, G) or Towne-BAC (B, D, F, H) foci undergoing fragmentation at 120 h (A–B, E–F) and 192 h (C–D, G–H) postinfection (MOI of
0.001). Arrows indicate SLCK-bound debris. Original magnification 6400 (A–H).
doi:10.1371/journal.ppat.1000063.g010
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studies have implicated HtrA2/Omi as a regulator of death
[35,37,40,89,90]. Genetic studies have suggested this protease
functions primarily to ensure normal mitochondrial homeostasis
[39,91,92], perhaps controlling protein quality and cellular stress
responses [34] similar to the related bacterial protease HtrA [41–
43]. The role of HtrA2/Omi in caspase-independent cell death
has not previously been studied in detail, although the truncated,
active form of HtrA2 drives death when released from mitochon-
dria or expressed directly in the cytoplasm [35,37,40,90,93]. We
have shown that the active form drives death specifically and only
in CMV-infected cells, which we correlate with the fact that the
enzyme remains mitochondrial throughout CMV infection. CMV
infection is a unique setting that has unveiled a direct role for
HtrA2/Omi in a caspase-independent cell death pathway
analogous to apoptosis.
vMIA controls the programmed death of infected cells after a
week or more of replication, following a period of persistent virus
production. CMV infects many cell types in addition to HFs, and
given that the timing of replication varies with cell type, vMIA
control of HtrA2/Omi-dependent death may be critical in other
cell types or in natural infection of the human host. Given the
many functions that CMV has evolved to manage the virus:host
standoff, we speculate that viral control of cmvPCD represents a
benefit to the virus, potentially allowing infected cells to avoid
sending alarm signals. Other examples of viral proteins acting
together to control the type of cell death that follows replication
can be identified. Thus, the adenovirus death protein, ADP,
functions in the presence of E1B-19k, the viral Bcl-2 protein, and
both contribute to the type of death that terminates infection [94–
96]. Caspase-dependent apoptosis is itself a cell-intrinsic pathogen
clearance process, minimizing inflammation and pathology while
alarming the immune system to initiate cellular responses [77].
CMV-encoded cell death suppressors provide a means of evading
cell death directed by host cell intrinsic, innate, and adaptive
responses [97]. The benefit of controlling the mechanism and
timing of cell death includes persistence, as well as the interface of
virus-infected cells with the host immune system. In the host,
cmvPCD may provide for greater success in attaining a foothold
without evoking clearance. The presence of vMIA-like functions in
other cytomegaloviruses [5,17] as well as the broad distribution of
mitochondrial cell death suppressors in other viruses suggests this
novel serine protease pathway may occur in other biological
settings.
Materials and Methods
Accession numbers
The HtrA2 protease has MEROPS accession number S01.278
and the I.M.A.G.E. consortium clone obtained for these studies
was identical in sequence to NCBI accession ID BC0000096. The
vMIA [2] used to complement and repair DUL37x1 was obtained
from AD169varATCC genomic DNA; NCBI accession ID
X17403. The sequence of Towne-BAC was deposited to NCBI
[8]; accession ID AY315197.
Cells and viruses
Human fibroblasts (HFs), vMIA-HFs, vMIAmut-HFs, and
HeLas were cultured as previously described [5]. Viruses derived
from the BACmid clones Towne-BAC and DUL37x1 [8] were
maintained as DNA clones in E. coli or on complementing vMIA-
HFs prior to experiments. AD169varATCC was maintained as
previously described [22].
Generation of DUL37x1 rescue virus RC2707
The kanamycin selection cassette in DUL37x1 was replaced
with UL37x1 sequence derived from AD169varATCC to generate
RC2707. Transfection of pON2707 [5] into HFs was followed by
infection with DUL37x1 virus. Plaques that included cell death at
a frequency similar to Towne-BAC virus [5] were isolated for
further analysis. Sequencing of viral DNA from Towne-BAC and
two independently derived isolates (DUL37x1R1, DUL37x1R2)
confirmed replacement of the selection marker in DUL37x1 with
UL37x1 nucleotide sequence identical to pON2707 and AD169-
varATCC while the control, Towne-BAC, was identical to the
expected sequence [8,98]. Expression of vMIA was confirmed by
immunoblot analysis.
Plasmids
The HtrA2/Omi expression plasmid, pON601, was derived by
restriction of the I.M.A.G.E. cDNA (HtraA2 clone #5344667,
ATCC, Manassas, VA) with BsrGI, followed by removal of the
single-stranded overhangs with Klenow DNA polymerase, and
restriction with XhoI. The HtrA2/Omi encoding fragment was
ligated to EcoRV and XhoI restricted pcDNA3.1+ (Invitrogen, San
Diego, CA). The HtrA2S306A expression plasmid, pON602, was
generated by PCR-site directed mutagenesis of the HtrA2 ORF to
introduce the S306A mutation and a novel NaeI restriction enzyme
site and utilized the mutagenic primer 59-CTATTGATTTTG-
GAAACGCCGGCGGTCCCCTGGTTAAC-39. Both clones
were sequenced to confirm expected results. The vMIA and GFP
expression clones and retroviral constructs used in these experiments
were reported previously [2,5,18].
Immunoblotting, immunofluorescence, and MitoTracker
Red staining assays
Immunodetection employed mouse monoclonal antibodies to c-
myc epitope (9E10; Santa Cruz Biotechnology, Santa Cruz, CA),
HtrA2/Omi (MAB1458; R&D Systems, Inc, Minneapolis, MN),
cytochrome c (Clone 7H8.2C12, BD Pharmingen, San Jose, CA),
b-actin (AC-74, Sigma, St. Louis, MO), golgin-97 (CDF4;
Molecular Probes, Eugene, OR), mitochondrial heat shock protein
70 (mtHSP70) (a gift from Susan Pierce, Northwestern University),
viral nuclear antigens IE1p72 and IE2p86 (MAB 810, Chemicon,
Temeculah, CA), ICP36 (CH16) and pp28 (CH19) (both from
Virusys Corporation, Randallstown, MD) or rabbit polyclonal
antiserum to native vMIA [2] and peroxidase-conjugated horse
anti-mouse IgG or goat anti-rabbit IgG, Texas Red-conjugated
horse anti-mouse IgG (all from Vector, Burlingame, Calif.), or
AlexaFluor 350-conjugated goat anti-mouse IgG (Molecular
Probes, Eugene, OR). Immunoblot analysis of total protein from
infected cells and immunofluorescence assays followed previously
described methods [22]. MitoTracker Red CMXRos (Molecular
Probes, Eugene, OR) staining of mitochondria followed previously
described methods [22].
Detection of cmvPCD, impact of replication and protease
inhibitors on death, viral yield, and BACmid transfections
To assess morphological changes in infected cells and nuclei, cells
grown on coverslips and infected for varying periods of time were
fixed with 3.7% formaldehyde, permeabilized with Triton X-100
(EMD Biosciences, Darmstadt, Germany), stained with Hoechst
33258 (AnaSpec, San Jose, CA), and processed for microscopic
evaluation as previously described [22]. Some cultures were stained
with ethidium homodimer 1 (Molecular Probes, Eugene, OR), as
previously described [5] to assess virus-induced cell death.
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described [5] or utilized Simple PCI software, a Retiga Exi digital
camera, and a Leica DM IRB microscope. Imaging of cultures
grown on coverslip employed an AxioCam MRc5 camera
attached to a Zeiss Axio Imager.A1 and AxioVision Release 4.5
software.
Replication inhibitors included phosphonoformate (PFA Sigma,
St. Louis, Mo) dissolved in water and 2-bromo-5,6-dichlorobenzi-
midazole (BDCRB from L. B. Townsend, University of Michigan)
dissolved in dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO).
Protease inhibitors included TLCK, N-alpha-p-tosyl-L-lysine
chloromethyl ketone, (Sigma, St. Louis, MO) in water, and
UCF-101 or zVAD.fmk (both from Calbiochem, La Jolla, CA)
dissolved in DMSO. Inhibitors were added by replacing culture
medium with medium containing inhibitor while control medium
included the appropriate solvent (DMSO) or no addition.
Morphology and presence of viral nuclear antigens IE1p72 and
IE2p86 were assessed as described above and viral yield was
determined from total virus recovered on day 7 from supernatant
and sonicated cells [5]. DMSO does not impact CMV death or
CMV replication levels at the concentrations used (#0.1%)[5].
Transfections of BACmid DNA have been described [5]. GFP-
positive (GFP+) cells and GFP-positive foci (.2 GFP+ cell) were
evaluated by live cell microscopy 2–10 days post transfection. Viral
presence was confirmed by immunodection of viral nuclear
antigens IE1p72 and IE2p86 and some experiments utilized a
plasmid encoding GFP [5] for detection of transfected cells.
Reported results were obtained from multiple DNA preparations.
Apoptosis and viability assays
Conditions for induced apoptosis of ADvarATCC infections and
vMIA-dependent survival following transfection of HeLa have
been described [2,64]. Cell numbers were determined following
Hoechst stain of surviving cells (HeLas) or following immunode-
tection of viral nuclear antigens IE1p72 and IE2p86 (ADvarATCC),
comparing to untreated controls.
To assess the impact of HtrA2/Omi on HFs, GFP expression
plasmid was cotransfected with control DNA (vector) or HtrA2/
Omi or HtrA2S306A expression plasmids. By 48 h cells had
recovered and were confluent. Images obtained of GFP fluores-
cence at 24 h intervals between 48–120 h post transfection were
evaluated for numbers of GFP+ cells from 12 microscopic fields
per day. Mean % survival (6standard deviation) was calculated
from numbers of GFP+ cells compared to those at 48 h.
SLCK labeling
Sulforhodamine 101-leucine chloromethyl ketone, SLCK,
(Immunochemistry Technologies, LLC, Bloomington, MN) was
suspended in DMSO (Sigma, St. Louis, MO). For labeling,
2.5 mM SLCK was applied in the presence or absence of TLCK to
live cultures for 30 minutes prior to fixation and imaging as
described above.
Supporting Information
Figure S1 Towne-BAC cmvPCD occurs after viral release.
Examples of single infected cells (A, B) or foci (C, D) remaining
intact and live (A, C) or exhibiting fragmentation and death
(cmvPCD) (B, D) are shown. Original magnification 6400. (E)
Percentages of single infected cells (patterns A+B) and foci
(patterns C+D) for DUL37x1 and Towne-BAC. (F) Percentages
of live, nonfragmented single cells or foci at 72, 96, or 120 h
postinfection (hpi) with DUL37x1 or Towne-BAC. (G) Percentages
of dead single cells or foci at 72, 96, or 120 hpi with DUL37x1 or
Towne-BAC. A total of 400 infected cells/foci per virus were
evaluated at each time for the experiment depicted in panels E–G
following infection at MOI 0.0001. The mean6sd is depicted in
all figures, except where indicated.
Found at: doi:10.1371/journal.ppat.1000063.s001 (1.84 MB TIF)
Figure S2 Nuclear and cytoplasmic inclusions indicate similar
late cytopathic effects in Towne-BAC and DUL37x1 infections.
Representative fluorescent images of nuclear and cytoplasmic
inclusion proteins ppUL44 (A, C) and ppUL28 (E, I) (red),
respectively, in DUL37x1 (A–B, E–H) and Towne-BAC (C–D, I–
L) infected cells (MOI of 0.001). (GFP=green, Hoechst=blue)
Original magnification 61000.
Found at: doi:10.1371/journal.ppat.1000063.s002 (6.21 MB TIF)
Figure S3 cmvPCD intermediates do not stain with ethidium
homodimer. Representative fluorescent images of GFP (A, E, I, M,
Q) (green), ethidium homodimer (B, F, J, N, R, U) (red), Hoechst
(C, G, K, O, S, V) (blue), and merged images (D, H, L, P, T, W) in
DUL37x1 infected intact (A–D) or fragmenting (E–T) cells stained
prior to fixation, and in controls fixed with methanol prior to
labeling (U, V, W). Original magnification 61000.
Found at: doi:10.1371/journal.ppat.1000063.s003 (2.45 MB TIF)
Figure S4 Towne-BAC death intermediates. Representative
fluorescent images of Towne-BAC infected cells (MOI of 0.01)
showing cmvPCD (A–D) at 168 h postinfection (hpi). Original
magnification 6400.
Found at: doi:10.1371/journal.ppat.1000063.s004 (1.99 MB TIF)
Figure S5 HtrA2/Omi expression following CMV infection.
Immunoblot analyses of HtrA2/Omi in lysates of mock-infected
HF (M) or HF infected (MOI of 3) with Towne-BAC or DUL37x1
for 24, 48, 72, 96, or 120 h. Control cell lysates from HeLa cells
transfected with HtrA2/Omi expression plasmid (+) or control
plasmid (2). Immunoblot detection of HtrA2, b-actin and IE1 are
shown.
Found at: doi:10.1371/journal.ppat.1000063.s005 (0.50 MB TIF)
Figure S6 Mitochondria are reticular in DUL37x1 and punctate
in Towne-BAC infections. Representative fluorescent images of
mitochondria HSP70 (mtHSP70) (A, E), golgin 97 (I, M), HtrA2/
Omi (Q, U), and cytochrome c (Y, c) (blue), and MitoTracker Red
stain of mitochondria (B, F, J, N, R, V, Z, d) (red), and GFP
fluorescence (C, G, K, O, S, W, a, e) (green) and merged images
(D, H, L, P, T, X, b, f) at 72 h postinfection (MOI of 0.001) with
DUL37x1 (A–D, I–L, Q–T, Y–b) or Towne-BAC (E–H, M–P, U–
X, c–f). Original magnification 61000.
Found at: doi:10.1371/journal.ppat.1000063.s006 (3.53 MB
DOC)
Figure S7 Reticular cytochrome c pattern maintained until after
initiation of cmvPCD. Representative fluorescent images of
cytochrome c (A, D, G, J, M), GFP fluorescence (B, E, H, K N)
and Hoechst (C, F, I, L, O) at 96 h postinfection (MOI of 0.001) in
fragmented DUL37x1 infected cells. Arrow in B indicates
fragments of GFP+ cell. Original magnification 61000.
Found at: doi:10.1371/journal.ppat.1000063.s007 (4.19 MB TIF)
Figure S8 HtrA2 overexpression in HeLa cells does not induce
death. GFP fluorescence following cotransfection of HF with GFP
expression plasmid together with empty vector, HtrA2/Omi or
HtrA2S306A expression plasmids at 24, 48, and 72 h posttrans-
fection. Original magnification x40.
Found at: doi:10.1371/journal.ppat.1000063.s008 (2.56 MB TIF)
Figure S9 HtrA2 reduces plaque formation following a decrease
in viability of infected cells evident by 72 h postinfection.
HtrA2/Omi and vMIA Control of cmvPCD
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tion of Towne-BAC DNA (500 ng) with 800 ng vector or HtrA2/
Omi expression plasmid.
Found at: doi:10.1371/journal.ppat.1000063.s009 (0.16 MB TIF)
Figure S10 vMIA impact on cmvPCD. (A) Total number of
DUL37x1 plaques on day 10 following infection at MOI 0.0001 of
HF, vMIAmut-HF, or vMIA-HF (B) Total viral yield following
infection of HF by DUL37x1, Towne-BAC, DUL37x1R1, or
DUL37x1R2 for 10 days at MOI 0.0001. (C–H) Mitochondria in
DUL37x1R1 and DUL37x1R2 infected cells at 72 h postinfection.
MitoTracker Red stain (C–F) (red), GFP fluorescence (D, G), and
the merged images. Original magnification 61000.
Found at: doi:10.1371/journal.ppat.1000063.s010 (4.66 MB TIF)
Figure S11 Serine proteases labeled with SLCK and impact of
TLCK added as inhibitor. Representative images of fluorescent
serine protease substrate SLCK localization (A–C) and GFP
fluorescence (D–F) in DUL37x1 foci undergoing fragmentation on
day 8 postinfection (MOI of 0.001) in the presence of no addition
(A, D), 100 mM TLCK (B, E), or 1 mM TLCK (C, F) Original
magnification 6200.
Found at: doi:10.1371/journal.ppat.1000063.s011 (4.49 MB TIF)
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